BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231129T130000
DTEND;TZID=America/New_York:20231129T140000
DTSTAMP:20260403T172852
CREATED:20231121T163230Z
LAST-MODIFIED:20231121T163230Z
UID:46010-1701262800-1701266400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Takeda - Overview of Adzynma (rADAMTS13) Prescribing Information
DESCRIPTION:Date: Wednesday\, November 29\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nOverview of Adzynma (rADAMTS13) Prescribing Information \nOBJECTIVE:\nInform on the new approval and prescribing information of Adzynma indicated for prophylactic and on-demand use for patients with congenital TTP. \nTARGET AUDIENCE:\nHematologists\, NPs\, nurses\, pharmacists \nSPEAKER:\n\nAli Mokdad\, MD\, PhD\, MBA\, Medical Director\, Takeda
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-overview-of-adzynma-radamts13-prescribing-information/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231127T130000
DTEND;TZID=America/New_York:20231127T140000
DTSTAMP:20260403T172852
CREATED:20231031T175111Z
LAST-MODIFIED:20231031T175452Z
UID:45934-1701090000-1701093600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from HEMA Biologics - A different treatment option for Inhibitor patients
DESCRIPTION:Date: Monday\, November 27\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nA different treatment option for Inhibitor patients \nOBJECTIVE:\nThis presentation will provide an overview of inhibitors and explore the efficacy\, safety\, tolerability\, clinical development\, and reasons to consider a different treatment option. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nGuy Young\, MD. \nDirector\, Hemostasis and Thrombosis Center\nDirector\, Clinical Coagulation Laboratory Cancer and Blood Disorders Institute Children’s Hospital Los Angeles\nProfessor of Pediatrics\, University of Southern California Keck School of Medicine
URL:https://hemoalliance.org/alliance-events/a-webinar-from-hemabiologics-a-different-treatment-option-for-inhibitor-patients/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231117T130000
DTEND;TZID=America/New_York:20231117T140000
DTSTAMP:20260403T172852
CREATED:20231025T210322Z
LAST-MODIFIED:20231025T210322Z
UID:45830-1700226000-1700229600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - An Informational Session from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
DESCRIPTION:Date: Friday\, November 17\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTOPIC:\nClinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® \nOVERVIEW:\nThis session includes key information about Jivi including\, safety and efficacy data from the clinical trials\, step-wise dosing and Jivi RWE Data from HEM-POWR\, a multinational\,open-label\, prospective\, non-interventional\, multicenter cohort study of Jivi®. \nThere will also be a review of the Q4 2023 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nMark T. Reding\, MD. \nDirector\, Center for Bleeding and Clotting Disorders\nProfessor of Medicine\, Division of Hematology\, Oncology\, and Transplantation\nUniversity of Minnesota \n\n\n\nFor additional important risk and use information\, please see the full Prescribing Information for Jivi.\nYou are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
URL:https://hemoalliance.org/alliance-events/an-informational-session-from-bayer-clinical-review-of-the-jivi-protect-viii-trial-and-insights-from-hem-powr-a-real-world-evidence-rwe/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231113T130000
DTEND;TZID=America/New_York:20231113T140000
DTSTAMP:20260403T172852
CREATED:20231107T161931Z
LAST-MODIFIED:20231107T161931Z
UID:45954-1699880400-1699884000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar on Hemgenix Real World Learnings from CSL Behring
DESCRIPTION:Date: Monday\, November 13\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nHemgenix Real World Learnings \nSPEAKER:\n\nVidhi Desai\, MD \nSenior Medical Director\, Coagulation\nNorth America Medical Affairs \nVidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head\, Director Medical Affairs for Coagulation Products in North America\, providing strategic and tactical medical leadership for Idelvion®\, Afstyla®  and Humate-P®\, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team. \nPrior to joining CSL Behring\, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, focusing primarily on benign hematologic disorders. \nVidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick\, NJ.
URL:https://hemoalliance.org/alliance-events/a-webinar-on-hemgenix-real-world-learnings-from-csl-behring/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231110
DTEND;VALUE=DATE:20231113
DTSTAMP:20260403T172852
CREATED:20230430T195240Z
LAST-MODIFIED:20230816T203938Z
UID:42903-1699574400-1699833599@hemoalliance.org
SUMMARY:🟥 Member Event : Physicians & Business Administrators Meeting
DESCRIPTION:Location: Redondo Beach\, California\nVenue: The Portofino Hotel & Marina \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727.688.2568. \n\nDRAFT AGENDA \nFriday: 8 am to 5 pm\nFor Business Administrators \n\nAlliance Services – an overview of what is offered by Hemophilia Alliance\n340B Refresher – Basic overview with answers to targeted questions\nUnderstanding Medicaid & Medicare – A look at the public payers and changes\nHANS – Why it’s important to have payer contracts\nWhy we need National Patient Org\nAdvocacy – Threats and Opportunities for HTCs\nUnderstanding GPO contracts\nRunning an HTC pharmacy – Having a Strategic Plan\nLegal Discussion – Understanding the challenges\n\n6 pm – Dinner \nSaturday: 8 am to 12:30 pm\nBusiness Course \nSunday: 8 am to 12:30 pm\nFor Clinical Providers \n\nStrengths: Leadership – How to work within an HTC\nWeakness: Relationships – How to work within a larger institute\nOpportunities: Risk – Going Independent\nThreats: Planning – Strategic Plan
URL:https://hemoalliance.org/alliance-events/2023-physicians-business-administrators-meeting/
LOCATION:The Portofino Hotel & Marina\, Redondo Beach\, 260 Portofino Way\, Redondo Beach\, CA\, 90277\, United States
CATEGORIES:Members Only
ORGANIZER;CN="Jeff Blake":MAILTO:jeff@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231109T130000
DTEND;TZID=America/New_York:20231109T140000
DTSTAMP:20260403T172852
CREATED:20230921T185243Z
LAST-MODIFIED:20230921T185243Z
UID:45676-1699534800-1699538400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Discussion from Genentech About Subcutaneous Prophylaxis Treatment for Hemophilia A
DESCRIPTION:Date: Thursday\, November 9\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nLearn More About Subcutaneous Prophylaxis Treatment for Hemophilia A:  A Discussion on the Latest Data and Patient Management \nDESCRIPTION:\nPlease join us for an engaging webinar led by Ketna Mistry\, MD who will be sharing information on patients with hemophilia A with a subcutaneous prophylaxis including the latest clinical data.  Ther presentation will include pivotal efficacy and safety data\, joint health data\, data in infants\, and an overview of real-world experience.  Be sure to bring your questions to have them answered during the Q&A following the program! \nSPEAKER:\n\nKetna Mistry\, MD \nMedical Director\, Hematology & Rare Blood Disorders\, U.S. Medical Affairs; Genentech \nDr. Mistry has 25 years of experience in her medical career\, as a physician caring for patients and teacher at Emory University\, a researcher at CDC\, and currently as a medical director at Genentech.  She completed medical school at Tulane University and graduated with honors from UCLA for her bachelor’s degree in psychobiology. She completed her internship and residency in pediatrics at University of Texas in Houston.  She is passionate about teaching and sharing information so that patients and providers can make the best informed decision for their care.
URL:https://hemoalliance.org/alliance-events/a-discussion-from-genentech-about-subcutaneous-prophylaxis-treatment-for-hemophilia-a/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231107T140000
DTEND;TZID=America/New_York:20231107T150000
DTSTAMP:20260403T172852
CREATED:20231023T165946Z
LAST-MODIFIED:20231023T165946Z
UID:45791-1699365600-1699369200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Pfizer - Case Studies of Using BeneFix® (Coagulation Factor IX [Recombinant]) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story?
DESCRIPTION:Date: Tuesday\, November 7\, 2023\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nCase Studies of Using BeneFix® (Coagulation Factor IX [Recombinant]) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story? \nSPEAKER:\n\nDoris Quon\, MD \nMedical Director of the Orthopaedic Hemophilia Treatment Center at the Luskin Orthopaedic Institute for Children in Los Angeles\, California
URL:https://hemoalliance.org/alliance-events/a-webinar-from-pfizer-case-studies-of-using-benefix-coagulation-factor-ix-recombinant-in-different-hemophilia-b-patient-populations-i/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231024T140000
DTEND;TZID=America/New_York:20231024T150000
DTSTAMP:20260403T172852
CREATED:20231003T184948Z
LAST-MODIFIED:20231005T175043Z
UID:45701-1698156000-1698159600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa\, A High Sustained Factor VIII Therapy
DESCRIPTION:Date: Tuesday\, October 24\, 2023\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nA Clinical Overview and Update from Sanofi for Efanesoctocog Alfa\, A High Sustained Factor VIII Therapy \nOBJECTIVES: \n\nHighlighting both Efanesoctocog Alfa’s pediatric study\, the XTEND-Kids data that were presented at ISTH 2023\, as well as an observational study of patients who switched from current therapy to Efanesoctocog Alfa prophylaxis.\nHighlighting available lab monitoring program available to your centers.\n\nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nNancy Epp\, PharmD\, BCACP \nNancy Epp is a Senior Medical Science Liaison with Sanofi. She supports the Sanofi hemophilia A and B portfolio to provide up-to-date scientific data to healthcare providers. Nancy is based in Houston\, Texas\, and can be reached by email at Nancy.Epp@sanofi.com.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-and-update-from-sanofi-for-efanesoctocog-alfa-a-high-sustained-factor-viii-therapy/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231018
DTEND;VALUE=DATE:20231021
DTSTAMP:20260403T172852
CREATED:20230227T161300Z
LAST-MODIFIED:20230320T213742Z
UID:41635-1697587200-1697846399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : ATHN Data Summit
DESCRIPTION:Date: October 18th – 20th (Atlanta\, GA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-athn-data-summit/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T130000
DTEND;TZID=America/New_York:20231012T140000
DTSTAMP:20260403T172852
CREATED:20230919T202008Z
LAST-MODIFIED:20230919T202008Z
UID:45606-1697115600-1697119200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview from Novo Nordisk - A Label Update on Rebinyn\, (Coagulation Factor IX (Recombinant)\, GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B
DESCRIPTION:Date: Thursday\, October 12\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nA Label Update on Rebinyn\, (Coagulation Factor IX (Recombinant)\, GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B \nOBJECTIVE:\nProvide a clinical review of Rebinyn that supports prophylaxis\, on-demand and perioperative indication in adults and children \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nParin Chikani\, PharmD\, MBA \nMedical Account Director\, Novo Nordisk Inc \nParin Chikani\, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago\, College of Pharmacy and his MBA from Kellstadt Graduate School of Business.  Before joining Novo Nordisk\, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business.  At Novo Nordisk\, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-from-novo-nordisk-a-label-update-on-rebinyn/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231008
DTEND;VALUE=DATE:20231011
DTSTAMP:20260403T172852
CREATED:20230105T220827Z
LAST-MODIFIED:20230615T184307Z
UID:39898-1696723200-1696982399@hemoalliance.org
SUMMARY:🟥 Member Event : Fall Members Meeting
DESCRIPTION:Venue: The St. Anthony Hotel\nLocation: San Antonio\, Texas \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568. \n\nDRAFT AGENDA: \n\nOct. 8th – Welcome Reception @ 6pm\nOct. 9th – Breakfast @ 7:30am; Meeeting:  8:30am – 5:00pm; Group Dinner @ 6:30 pm\nOct. 10th – Breakfast @ 7:30am; Meeeting:  8:30am – 3:30pm
URL:https://hemoalliance.org/alliance-events/2023-fall-members-meeting/
LOCATION:The St. Anthony Hotel\, San Antonio\, 300 East Travis Street\, San Antonio\, TX\, 78205\, United States
CATEGORIES:Members Only
ORGANIZER;CN="Jeff Blake":MAILTO:jeff@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231004T130000
DTEND;TZID=America/New_York:20231004T140000
DTSTAMP:20260403T172853
CREATED:20230919T202042Z
LAST-MODIFIED:20230919T202042Z
UID:45601-1696424400-1696428000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview from Novo Nordisk - An injectable\, extended half-life recombinant\, glycopegylated factor VIII concentrate for Hemophilia A
DESCRIPTION:Date: Wednesday\, October 4\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nAn injectable\, extended half-life recombinant\, glycopegylated factor VIII concentrate for Hemophilia A \nOBJECTIVE:\nProvide a clinical overview of Esperoct that supports prophylactic\, on-demand and perioperative management indications in adults and children. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nParin Chikani\, PharmD\, MBA \nMedical Account Director\, Novo Nordisk Inc \nParin Chikani\, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago\, College of Pharmacy and his MBA from Kellstadt Graduate School of Business.  Before joining Novo Nordisk\, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business.  At Novo Nordisk\, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-from-novo-nordisk-on-esperoct/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230920T130000
DTEND;TZID=America/New_York:20230920T140000
DTSTAMP:20260403T172853
CREATED:20230911T150045Z
LAST-MODIFIED:20230911T150045Z
UID:45518-1695214800-1695218400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Case Discussion from Takeda on Adult Severe Type 3 von Willebrand Disease Patient
DESCRIPTION:Date: Wednesday\, September 20\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nCase Discussion: Adult Severe Type 3 von Willebrand Disease Patient \nOBJECTIVE:\nIn case you missed it at the National Bleeding Disorders Foundation conference\, join expert Dr. Jonathan Roberts\, MD for an interactive discussion about managing patients who are living with von Willebrand Disease (VWD). Dr. Roberts will guide you through a VWD case-based experience\, including reviewing treatment history and a treatment option for prophylaxis.  \nTARGET AUDIENCE:\nHematologists\, nurses\, pharmacists\, and other stakeholders with medical credentials \nSPEAKER:\n\nDr. Jonathan C. Roberts\, MD \nDr. Roberts is the Associate Medical Director/Associate Research Director of Bleeding and Clotting Disorders Institute in Peoria IL. Dr. Roberts is also an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine. \nHis research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia\, VWD\, and other rare bleeding and classical hematologic disorders.
URL:https://hemoalliance.org/alliance-events/a-case-discussion-from-takeda-on-adult-severe-type-3-von-willebrand-disease-patient/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230918
DTEND;VALUE=DATE:20230923
DTSTAMP:20260403T172853
CREATED:20230410T144810Z
LAST-MODIFIED:20230920T165535Z
UID:42804-1694995200-1695427199@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2023 Partners Physician Academy
DESCRIPTION:Date: September 18th – 22nd\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2023-partners-physician-academy/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230822T140000
DTEND;TZID=America/New_York:20230822T150000
DTSTAMP:20260403T172853
CREATED:20230813T212537Z
LAST-MODIFIED:20230813T212537Z
UID:44933-1692712800-1692716400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - Simplifi 797 for Hemophilia Alliance member HTC pharmacies
DESCRIPTION:Date: Tuesday\, August 22\, 2023\nTime: 2:00pm – 3:00pm ET \n \nThe webinar will review how to stay compliant with USP 797 \n\nSOP’s\nTraining\nCompetencies\nTask Management\nReporting\nAlerting\nElimination of Blind Spots\n\nPlease contact Mark Plencner at mark@hemoalliance.org with questions.
URL:https://hemoalliance.org/alliance-events/simplifi-797-for-hemophilia-alliance-member-htc-pharmacies/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230817
DTEND;VALUE=DATE:20230820
DTSTAMP:20260403T172853
CREATED:20230227T161134Z
LAST-MODIFIED:20230320T213753Z
UID:41633-1692230400-1692489599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : NHF BDC 2023
DESCRIPTION:Date: August 17th – 19th (National Harbor\, MD)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-nhf-bdc-2023/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230808T130000
DTEND;TZID=America/New_York:20230808T140000
DTSTAMP:20260403T172853
CREATED:20230801T142843Z
LAST-MODIFIED:20230801T142843Z
UID:44804-1691499600-1691503200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - HTC Preparation for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) from BioMarin
DESCRIPTION:Date: Tuesday\, August 8\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nHTC preparation for ROCTAVIAN ™ (valoctocogene roxaparvovec-rvox)  \nOBJECTIVE:\nLearn about eligibility testing\, ordering\, storing\, handling and administering ROCTAVIAN \nTARGET AUDIENCE:\nHTC staff interested in learning about ROCTAVIAN’s clinical and logistical requirements \nSPEAKER:\n\nHenry Mead PhD\, MBA\, MPA\nSenior Director\, BioMarin Hemophilia North America Medical Affairs \nHenry Mead has worked in medical affairs for over two decades in North America and globally. Over the last 15 years it has been his privilege to work closely with hemophilia researchers\, clinical investigators\, patient advocates\, and hemophilia nurses. His experience includes leading medical affairs team’s ensuring they adhere to the principles of credible\, accurate and balanced scientific dissemination of data to external customers. Additionally\, identifying\, vetting\, and supporting investigator-initiated research and publishing relevant findings has been an important component of knowledge transfer activities.
URL:https://hemoalliance.org/alliance-events/htc-preparation-for-roctavian-valoctocogene-roxaparvovec-rvox-from-biomarin/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230713T140000
DTEND;TZID=America/New_York:20230713T150000
DTSTAMP:20260403T172853
CREATED:20230706T203149Z
LAST-MODIFIED:20230713T131312Z
UID:44259-1689256800-1689260400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Gene Therapy Update
DESCRIPTION:Date: Thursday\, July 13\, 2023\nTime: 2:00pm – 3:00pm ET \n \nTOPIC:\nGene Therapy Update \nOBJECTIVES: \n\nReview the status of Roctavian and Hemgenix\, gene therapy products and the Alliance contracts with the Biomarin and CSL.\nProvide information on how to obtain the products and ensure they are infusion ready.\nExamine the rationale behind Biomarin’s decision to use Specialty Pharmacies and TAP for distribution and discuss how using TAP would benefit Hemophilia Treatment Centers (HTCs).\nConduct a comprehensive review of the Alliance Contract with CSL and Biomarin.\nCompare and analyze the pricing model and rebate program offered by Biomarin and CSL\, specifically in relation to gene therapy products.\n\nWe encourage you to submit questions ahead of time you would like to be answered or are just curious about. \nSPEAKER:\n\nJoe Pugliese\, President & CEO Hemophilia Alliance
URL:https://hemoalliance.org/alliance-events/member-webinar-hemophilia-alliance-presents-gene-therapy-update/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230710
DTEND;VALUE=DATE:20230713
DTSTAMP:20260403T172853
CREATED:20230227T161001Z
LAST-MODIFIED:20230320T213801Z
UID:41631-1688947200-1689206399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 340B Coalition Summer Conference
DESCRIPTION:Date: July 10th – 12th (Washington\, DC)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-340b-coalition-summer-conference/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230629T140000
DTEND;TZID=America/New_York:20230629T150000
DTSTAMP:20260403T172853
CREATED:20230621T134555Z
LAST-MODIFIED:20230620T184048Z
UID:43883-1688047200-1688050800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - Value Based Agreements with Payers from Takeda
DESCRIPTION:Date: Thursday\, June 29\, 2023\nTime: 2:00pm – 3:00pm ET \n\n \nTOPIC:\nValue Based Agreements with Payers \nOBJECTIVES:\nTakeda is excited to share more information about the transition from transactional relationships with payers to value based agreements in a real world example. Mark will provide an overview of how these agreements work\, the metrics used\, and how that fits with hematology. Takeda’s goal is to provide additional perspective on a complicated payer landscape.  \nSPEAKER:\n\nMark Gimbert\, VP Specialty Pharmacy and Channel Management at Takeda \nMark started at Takeda in 1999 as a sales representative and has held various roles of increasing responsibility. He pioneered a Strategic Partnerships Function within Takeda\, focused on accelerating Partner for Access imperatives\, construct value-based contracts\, and identify tools and resources to assist patients with access to medications. In his current role\, Mark has full accountability for leadership and management of all U.S. Managed Markets Specialty Pharmacy relationships\, strategic direction\, and access.
URL:https://hemoalliance.org/alliance-events/value-based-agreements-with-payers-from-takeda/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230624
DTEND;VALUE=DATE:20230629
DTSTAMP:20260403T172853
CREATED:20230227T160741Z
LAST-MODIFIED:20230320T213807Z
UID:41629-1687564800-1687996799@hemoalliance.org
SUMMARY:🟦 Non-Member Event : ISTH 2023 Congress
DESCRIPTION:Date: June 24th – 28th (Montreal\, Canada)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-isth-2023-congress/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230616
DTEND;VALUE=DATE:20230619
DTSTAMP:20260403T172853
CREATED:20230227T160603Z
LAST-MODIFIED:20230320T213815Z
UID:41627-1686873600-1687132799@hemoalliance.org
SUMMARY:🟦 Non-Member Event : Texas Bleeding Disorders Conference
DESCRIPTION:Date: June 16th – 18th (San Antonio\, TX)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-texas-bleeding-disorders-conference/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230615T133000
DTEND;TZID=America/New_York:20230615T143000
DTSTAMP:20260403T172853
CREATED:20230605T190932Z
LAST-MODIFIED:20230606T203501Z
UID:43551-1686835800-1686839400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - Discover ALTUVIIIO™\, A New Treatment Option for Your Patients from Sanofi
DESCRIPTION:Date: Thursday\, June 15\, 2023\nTime: 1:30pm – 2:30pm ET \n\n \nTOPIC:\nDiscover ALTUVIIIO™\, A New Treatment Option for Your Patients\, and the Customized Support Services Designed to Assist You \nOBJECTIVES: \n\nProvide background and education on the science behind ALTUVIIIO™ and how to apply it to your clinical practice\nUnderstand the roles and resources that Sanofi’s Patient Support Services Team has to support patients throughout their treatment journey\n\nSPEAKER:\n\nVivek Sharma\, MD\, FACP\nAssociate Professor\nDivision of Hematology/Oncology\nUniversity of Louisville \nVivek R Sharma\, MD\, FACP is an Associate Professor at the University of Louisville at the Division of Hematology/Oncology. He completed his medical school in India and his Internal Medicine Residency as well as Heme/Onc Fellowship at the University of Louisville. He is the Medical Director of the Adult Hemophilia program in Louisville and also has interest in other rare hematological diseases.
URL:https://hemoalliance.org/alliance-events/discover-altuviiio-a-new-treatment-option-for-your-patients-from-sanofi/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230612
DTEND;VALUE=DATE:20230614
DTSTAMP:20260403T172853
CREATED:20230105T220700Z
LAST-MODIFIED:20230320T213821Z
UID:39896-1686528000-1686700799@hemoalliance.org
SUMMARY:🟥 Member Event : Hemophilia Alliance Hill Day
DESCRIPTION:Location: Washington\, DC \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727.688.2568.
URL:https://hemoalliance.org/alliance-events/2023-hemophilia-alliance-hill-day/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230513
DTSTAMP:20260403T172853
CREATED:20230410T144355Z
LAST-MODIFIED:20230410T144355Z
UID:42802-1683676800-1683935999@hemoalliance.org
SUMMARY:🟦 Non-Member Event : WFH 2023 Comprehensive Care Summit
DESCRIPTION:Date: May 10th – 12th (Buenos Aires\, Argentina)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/%f0%9f%9f%a6-non-member-event-wfh-2023-comprehensive-care-summit/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230513
DTSTAMP:20260403T172853
CREATED:20230105T220540Z
LAST-MODIFIED:20230320T213828Z
UID:39894-1683676800-1683935999@hemoalliance.org
SUMMARY:🟥 Member Event : New HTC Staff Meeting
DESCRIPTION:Location: New York City\, NY\nPlease confirm that you can commit to attend the entire meeting before registering. \n\nIf you have questions regarding this registration please contact Sean Singh at sean@hemoalliance.org / 813-748-7226 or Theresa Parker at theresa@hemoalliance.org / 727-688-2568.
URL:https://hemoalliance.org/alliance-events/2023-new-htc-staff-meeting/
LOCATION:The Westin New York Grand Central\, 212 East 42nd Street\, New York\, NY\, 10017\, United States
CATEGORIES:Members Only
ORGANIZER;CN="Jeff Blake":MAILTO:jeff@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230426
DTEND;VALUE=DATE:20230430
DTSTAMP:20260403T172853
CREATED:20221208T233207Z
LAST-MODIFIED:20230324T144604Z
UID:38627-1682467200-1682812799@hemoalliance.org
SUMMARY:🟥 Member Event : 25th Annual Linda Gammage Social Worker Conference
DESCRIPTION:Date: April 26th – 29th\nLocation: San Mateo\, California\nVenue: San Mateo Marriott San Francisco Airport \n\nPlease contact Jeff Amond with any questions regarding this registration at amond@hemoalliance.org or 608-206-3132.
URL:https://hemoalliance.org/alliance-events/hemophilia-alliance-presents-25th-annual-linda-gammage-social-worker-conference/
LOCATION:San Mateo Marriott San Francisco Airport\, 1770 South Amphlett Blvd\, San Mateo\, CA\, 94402\, United States
CATEGORIES:Members Only
ORGANIZER;CN="Jeff Amond":MAILTO:amond@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230417T130000
DTEND;TZID=America/New_York:20230417T140000
DTSTAMP:20260403T172853
CREATED:20230404T145401Z
LAST-MODIFIED:20230404T145609Z
UID:42626-1681736400-1681740000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Implementation of New Medicare Hemophilia SNF Policy – HTC Strategies That Worked
DESCRIPTION:Date: Monday\, April 17\, 2023\nTime: 1:00pm – 2:00pm ET\nClick here to register
URL:https://hemoalliance.org/alliance-events/implementation-of-new-medicare-hemophilia-snf-policy-htc-strategies-that-worked/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230413
DTEND;VALUE=DATE:20230417
DTSTAMP:20260403T172853
CREATED:20230227T160213Z
LAST-MODIFIED:20230320T213840Z
UID:41625-1681344000-1681689599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : HFA Annual Symposium
DESCRIPTION:Date: April 13th – 16th (Orlando\, FL)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-hfa-annual-symposium/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230405T130000
DTEND;TZID=America/New_York:20230405T140000
DTSTAMP:20260403T172853
CREATED:20230320T195950Z
LAST-MODIFIED:20230404T145752Z
UID:42040-1680699600-1680703200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - Considerations for Jivi as the next rFVIII product from Bayer
DESCRIPTION:Date: Wednesday\, April 5\, 2023\nTime: 1:00pm – 2:00pm ET\nClick here to register
URL:https://hemoalliance.org/alliance-events/%f0%9f%9f%a5member-webinar-hemophilia-alliance-hosts-considerations-for-jivi-as-the-next-rfviii-product-from-bayer/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR